KRAS and colorectal carcinoma: In CRC, ERK activity is supposedly more cell-autonomous due to oncogenic mutations activating KRAS, NRAS or BRAF (found in 45, 5 and 10% of CRCs, respectively)5,6, or by de novo expression of EGFR ligands such as amphiregulin7.